Trimebutine Maleate
ApprovedSmall molecule
Trimebutine Maleate is one of 71 small molecule programs targeting Post Operative Nausea and Vomiting. It is currently in Approved.
2
Indications
2
Total Trials
0
Active Trials
70
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
54 competitors in Esophagitis
#DrugCompanyPhaseTrials
1Prevacid
TakedaApproved
Dexilant
TakedaApproved
Nexium
DDexcel Pharma Technologies Ltd.
Approved
Flovent
GSKApproved
Aciphex
Akero TherapeuticsApproved
Protonix
WWyeth-Lederle Vaccines
Approved
Mucosta
OtsukaApproved
Pulmicort
SSalix
Approved
Alka-Seltzer
AAbbott
Approved
Esomeprazole Mg
AstraZenecaApproved
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Esophagitis1 trial
Post Operative Nausea and Vomiting1 trial
Study of Trimebutine Maleate (NEWBUTIN SR 300 mg Tab)for Treatment of Post Operative Nausea and Vomiting
Unknown status·—·Phase 3·NCT01984931·45 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Trimebutine Maleate. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details